This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Stealth BioTherapeutics Management

Management criteria checks 1/4

Key information

Reenie McCarthy

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.1yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO

Reenie McCarthy (57 yo)

4.1yrs

Tenure

Ms. Irene P. McCarthy, also known as Reenie, J.D., has been President, Chief Executive Officer and Secretory of Stealth BioTherapeutics Corp (formerly known as Stealth BioTherapeutics Inc.) since October 2...

Board Members

Name	Position	Tenure	Compensation	Ownership
Irene McCarthy	President	4.4yrs	no data	0.19% $ 45.9k
Francis Chen	Independent Non-Employee Director	4.4yrs	no data	0% $ 0
Kevin McLaughlin	Independent Non-Employee Director	4.4yrs	no data	0% $ 0
Louis Lange	Independent Director	3.3yrs	no data	0% $ 0
Lokchung R. Chan	Chairman of the Board	4.4yrs	no data	0% $ 0
Eve Slater	Director	1.9yrs	no data	0% $ 0
Edward Owens	Non-Employee Director	5.3yrs	no data	0.11% $ 25.9k

4.4yrs

Average Tenure

72yo

Average Age

Experienced Board: S1BA's board of directors are considered experienced (4.4 years average tenure).

This company listing is no longer active

Stealth BioTherapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces Departure of Robert Weiskopf as Chief Financial Officer

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces Promotion of Marty Redmon to Chief Research & Development Officer

Stealth BioTherapeutics Corp Announces Board and Committee Changes

Recent updates

Stealth BioTherapeutics Corp(NasdaqGM:MITO) dropped from NASDAQ Composite Index

J. Wood Capital Advisors LLC and Morningside Venture (I) Investments Limited completed the acquisition of 22.5293% stake in Stealth BioTherapeutics Corp (NasdaqGM:MITO).

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis

Stealth BioTherapeutics Corp Announces Departure of Robert Weiskopf as Chief Financial Officer

Stealth BioTherapeutics Announces Receipt of Non-Compliance Notice from Nasdaq

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

Stealth BioTherapeutics Corp Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022

Stealth Biotherapeutics Announces Data from Reclaim-2 Phase 2 Trial of Elamipretide in Geographic Atrophy

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces New SBT-272 Data and Trial Initiation

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Requirement

Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid and Market Value Requirements

Stealth Bio Therapeutics Provides Update on Clinical Stage Rare Disease Programs

Stealth BioTherapeutics Corp Presents Positive Elamipretide Data in Pediatric Cardiology At International Society for Heart Research North American Section Meeting 2021

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021

Stealth Biotherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome

Stealth Biotherapeutics Corp Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration At the 2021 Arvo Annual Meeting

Stealth BioTherapeutics Corp Announces Promotion of Marty Redmon to Chief Research & Development Officer

Stealth BioTherapeutics Corp Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy

New 90-day high: €1.53

New 90-day high: €1.39

Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As Treatment For Cardiomyopathy In Barth Syndrome

New 90-day high: €1.27

Stealth BioTherapeutics Corp Announces Board and Committee Changes

New 90-day low: €1.02

Revenue in line with expectations

New 90-day low: €1.03

Revenue in line with expectations

Stealth Biotherapeutics Announces Development Financing to Advance Elamipretide Clinical Trials

Stealth BioTherapeutics Corp to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.08

Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting

New 90-day low - €1.21

New 90-day low - €1.46

Stealth BioTherapeutics Corp to Report Q2, 2020 Results on Aug 06, 2020

CEO

Tenure

Board Members

Average Tenure

Average Age